ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT
April 17, 2024 18:22 ET
|
The Rosen Law Firm PA
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
April 17, 2024 07:30 ET
|
Faruqi & Faruqi LLP
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint”...
DEADLINE ALERT for HRT, CKPT, and SOND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
April 15, 2024 12:07 ET
|
The Law Offices of Frank R. Cruz
LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
April 12, 2024 10:20 ET
|
Faruqi & Faruqi LLP
NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Checkpoint Therapeutics, Inc. (“Checkpoint”...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT
April 11, 2024 18:44 ET
|
The Rosen Law Firm PA
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 22, 2024 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
March 18, 2024 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
January 29, 2024 08:00 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 11, 2024 08:15 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
December 05, 2023 08:30 ET
|
Checkpoint Therapeutics, Inc
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....